Review Article
Research progress on tumor hyperthermia
Zhao Yanyan, Xu Yasi, Wu Qiong, Ma Shenglin, Zhang Shirong
Published 2021-08-15
Cite as Chin J Radiat Oncol, 2021, 30(8): 862-866. DOI: 10.3760/cma.j.cn113030-20200107-00010
Abstract
In recent years, increasing evidence has shown that hyperthermia is safe, effective and causes low toxicity. Hyperthermia can exert synergistic effect with other treatments, such as radiotherapy and chemotherapy. It has become an important adjuvant anti-tumor treatment secondary to surgery, chemotherapy, radiotherapy and biological treatment. Hyperthermia can improve the efficacy of radiotherapy and chemotherapy by directly inhibiting tumor cells and heat-induced radiosensitizing effect. Hence, hyperthermia is gradually applied in the multimodality treatment of tumors. In this article, we intend to review the research progress on the application of tumor hyperthermia in conventional radiotherapy, chemotherapy, immunotherapy and new biomaterials.
Key words:
Neoplasm/hyperthermia; Neoplasm/chemotherapy; Neoplasm/radiotherapy; Neoplasm/immunotherapy; Biomaterials
Contributor Information
Zhao Yanyan
Department of Translation Medicine Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People′s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
Xu Yasi
Department of Translation Medicine Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People′s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
Wu Qiong
Department of Translation Medicine Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People′s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
Ma Shenglin
Department of Translation Medicine Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People′s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China
Zhang Shirong
Department of Translation Medicine Center, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People′s Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China